RBC Capital analyst Kennen MacKay weighed in on Alexion Pharmaceuticals (NASDAQ: ALXN) saying they see Chugai's recently-filed patent infringement lawsuit ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE